SCHEMBL6403464

SCHEMBL6403464

O=C(Cc1cccc(O)c1)c1c(O)cccc1OP(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 1/20 0.41
INPP5B P32019 1/20 0.41
INPP5A Q14642 1/20 0.41
CTBP2 P56545 1/20 0.40
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
MAOB P27338 2/20 0.39
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PDE3A Q14432 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HIF1A Q16665 1/20 0.36
TYR P14679 1/20 0.36
SPR P35270 1/20 0.36
PPIA P62937 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395053 0.88 MAPT (0.47) INPPL1INPP5BINPP5ACTBP2HPGD
SCHEMBL6403786 0.87 SLC5A1 (0.45) INPPL1INPP5BINPP5AHPGDMEN1
SCHEMBL6398669 0.86 ACHE (0.43) INPPL1INPP5BINPP5AHPGDMEN1
SCHEMBL6395137 0.85 ACHE (0.47) MEN1GAAMAPTKMT2AALDH1A1
SCHEMBL6396414 0.80 HIF1A (0.44) INPPL1INPP5BINPP5ACTBP2HPGD
SCHEMBL6399091 0.80 HIF1A (0.44) INPPL1INPP5BINPP5ACTBP2HPGD
SCHEMBL6404380 0.80 CTBP2 (0.42) CTBP2HPGDMEN1GAAMAPT
SCHEMBL6398853 0.77 HDAC4 (0.36) INPPL1INPP5BINPP5AHPGDMAOB
SCHEMBL6399390 0.76 SLC5A1 (0.54) HPGDMEN1GAAMAPTKMT2A
SCHEMBL6404374 0.76 LMNA (0.41) CTBP2HPGDMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 INPPL1 85/4885INPP5B 137/4885INPP5A 190/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.